產(chǎn)品詳情
簡單介紹：
重組鼠白介素-21蛋白與其它公司提供的重組蛋白不同，rMuIL-21蛋白產(chǎn)品為采用CFS的無細胞麥胚蛋白合成系統(tǒng)表達出來的重組蛋白，可表達出對細胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時獨有的全自動蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組鼠白介素-21蛋白（全長序列）產(chǎn)品可用于Western Blot驗證、抗體制備、蛋白檢測、ELISA等試驗中.
詳情介紹：
重組鼠白介素-21蛋白
| Species | Murine |
| Accession | Q9ES17 |
| GeneID | 60505 |
| Source | Escherichia coli. |
| Molecular Weight | Approximately 15.0 kDa, a single non-glycosylated polypeptide chain containing 129 amino acids. |
| Quantity | 2μg/10μg/1000μg |
| AA Sequence | 重組鼠白介素-21蛋白HKSSPQGPDR LLIRLRHLID IVEQLKIYEN DLDPELLSAP QDVKGHCEHA AFACFQKAKL KPSNPGNNKT FIIDLVAQLR RRLPARRGGK KQKHIAKCPS CDSYEKRTPK EFLERLKWLL QKMIHQHLS |
| Purity | > 98 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human N1186 T cells is less than 25 ng/ml, corresponding to a specific activity of > 4.0 × 104 IU/mg. |
| Physical Appearance | 重組鼠白介素-21蛋白Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 μm filtered concentrated solution in 2 × PBS, pH 7.4. |
| Endotoxin | Less than 0.1 EU/μg of rMuIL-21 as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | 重組鼠白介素-21蛋白This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組鼠白介素-21蛋白 | |
| SDS-PAGE |
|
